DE602005016946D1 - Muteine des fibroblasten-wachstumsfaktors 21 - Google Patents

Muteine des fibroblasten-wachstumsfaktors 21

Info

Publication number
DE602005016946D1
DE602005016946D1 DE602005016946T DE602005016946T DE602005016946D1 DE 602005016946 D1 DE602005016946 D1 DE 602005016946D1 DE 602005016946 T DE602005016946 T DE 602005016946T DE 602005016946 T DE602005016946 T DE 602005016946T DE 602005016946 D1 DE602005016946 D1 DE 602005016946D1
Authority
DE
Germany
Prior art keywords
muteins
growth factor
fibroblast growth
mutines
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005016946T
Other languages
English (en)
Inventor
Christopher Carl Frye
Lihua Huang
Radmila Micanovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE602005016946D1 publication Critical patent/DE602005016946D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE602005016946T 2004-09-02 2005-07-26 Muteine des fibroblasten-wachstumsfaktors 21 Active DE602005016946D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60680504P 2004-09-02 2004-09-02
PCT/US2005/026398 WO2006028595A2 (en) 2004-09-02 2005-07-26 Muteins of fibroblast growth factor 21

Publications (1)

Publication Number Publication Date
DE602005016946D1 true DE602005016946D1 (de) 2009-11-12

Family

ID=36036790

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005016946T Active DE602005016946D1 (de) 2004-09-02 2005-07-26 Muteine des fibroblasten-wachstumsfaktors 21

Country Status (21)

Country Link
US (1) US7582607B2 (de)
EP (2) EP2161281A1 (de)
JP (1) JP4809352B2 (de)
KR (1) KR100854198B1 (de)
CN (1) CN101010338B (de)
AT (1) ATE444307T1 (de)
AU (1) AU2005283025B2 (de)
BR (1) BRPI0514790A (de)
CA (1) CA2575753A1 (de)
DE (1) DE602005016946D1 (de)
DK (1) DK1789442T3 (de)
EA (1) EA011390B1 (de)
ES (1) ES2332057T3 (de)
HR (1) HRP20090597T1 (de)
IL (1) IL181573A0 (de)
MX (1) MX2007002616A (de)
NO (1) NO20071327L (de)
PL (1) PL1789442T3 (de)
PT (1) PT1789442E (de)
SI (1) SI1789442T1 (de)
WO (1) WO2006028595A2 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
CA2574953A1 (en) 2004-07-26 2006-02-09 Dow Global Technolgies Inc. Process for improved protein expression by strain engineering
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
ATE554785T1 (de) 2007-03-30 2012-05-15 Ambrx Inc Modifizierte fgf-21 polypeptide und ihre verwendung
WO2008134461A2 (en) 2007-04-27 2008-11-06 Dow Global Technologies, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
JP2010535781A (ja) * 2007-08-03 2010-11-25 イーライ リリー アンド カンパニー 肥満に対する処置
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
WO2010042747A2 (en) 2008-10-10 2010-04-15 Amgen Inc. Fgf21 mutants and uses thereof
WO2011089170A2 (en) 2010-01-22 2011-07-28 Novo Nordisk A/S Process for preparing fgf-21 with low degree of o-glycosylation
US9120871B2 (en) 2009-01-23 2015-09-01 Novo Nordisk A/S Process for preparing FGF21 with low degree of O-glycosylation
EP2389190B1 (de) 2009-01-23 2018-09-19 Novo Nordisk A/S Fgf21-derivate mit albuminbinder a-b-c-d-e- und deren verwendung
JO3469B1 (ar) * 2009-05-05 2020-07-05 Amgen Inc طافرات fgf21 واستخداماتها
MX2011011815A (es) 2009-05-05 2012-01-27 Amgen Inc Mutantes fgf21 y usos de los mismos.
CA2764835A1 (en) * 2009-06-17 2010-12-23 Amgen Inc. Chimeric fgf19 polypeptides and uses thereof
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
JP2013512672A (ja) * 2009-12-02 2013-04-18 アムジエン・インコーポレーテツド ヒトＦＧＦＲ１ｃ、ヒトβ−クロト−、ならびにヒトＦＧＦＲ１ｃおよびヒトβ−クロト−の両方に結合する結合タンパク質
UA109888C2 (uk) * 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
EP2460527A1 (de) 2010-01-21 2012-06-06 Sanofi Pharmazeutische Zusammensetzung zur Behandlung eines metabolischen Syndroms
CA2796055A1 (en) 2010-04-15 2011-10-20 Amgen Inc. Human fgf receptor and .beta.-klotho binding proteins
US20130116171A1 (en) 2010-04-16 2013-05-09 Salk Institute For Biological Studies Methods for treating metabolic disorders using fgf
JP2013533227A (ja) 2010-06-08 2013-08-22 ノヴォ ノルディスク アー／エス Ｆｇｆ２１類似体および誘導体
EP2595647A1 (de) 2010-07-20 2013-05-29 Novo Nordisk A/S N-terminal-modifizierte fgf21-verbindungen
RU2013118441A (ru) 2010-11-05 2014-12-10 КовЭкс Текнолоджиз Айэлэнд Лимитед Антидиабетические соединения
US9023791B2 (en) * 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
MY163674A (en) 2011-07-01 2017-10-13 Ngm Biopharmaceuticals Inc Compositions, uses and method for treatment of metabolic disorders and diseases
EP2548570A1 (de) 2011-07-19 2013-01-23 Sanofi Pharmazeutische Zusammensetzung zur Behandlung eines metabolischen Syndroms
UY34346A (es) * 2011-09-26 2013-04-30 Novartis Ag Proteínas de fusión para tratar trastornos metabólicos
AR087973A1 (es) 2011-10-04 2014-04-30 Lilly Co Eli Variantes del factor 21 del crecimiento de fibroblastos
SG11201402640SA (en) 2011-12-22 2014-10-30 Pfizer Anti-diabetic compounds
EP2814844B1 (de) 2012-02-15 2017-08-02 Novo Nordisk A/S Antikörper, die den auslösenden rezeptor binden und blockieren, der auf myeloid-zellen-1 (trem-1) exprimiert ist
WO2013120554A1 (en) 2012-02-15 2013-08-22 Novo Nordisk A/S Antibodies that bind peptidoglycan recognition protein 1
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
US9475856B2 (en) 2012-03-02 2016-10-25 New York University Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders
US9464126B2 (en) 2012-06-07 2016-10-11 New York University Chimeric fibroblast growth factor 21 proteins and methods of use
US9474785B2 (en) 2012-06-07 2016-10-25 New York University Chimeric fibroblast growth factor 19 proteins and methods of use
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
CA2871656A1 (en) 2012-06-11 2013-12-19 Eli Lilly And Company Fibroblast growth factor 21 variants
NZ630484A (en) 2012-11-28 2017-04-28 Ngm Biopharmaceuticals Inc Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
SG10202100667SA (en) 2012-12-27 2021-02-25 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2014130659A1 (en) 2013-02-22 2014-08-28 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
US9925241B2 (en) 2013-10-21 2018-03-27 Salk Institute For Biological Studies Mutated fibroblast growth factor (FGF) 1 and methods of use
WO2015061331A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
CN105828878A (zh) 2013-10-28 2016-08-03 恩格姆生物制药公司 癌症模型及相关方法
RU2701434C2 (ru) 2014-01-24 2019-09-26 Нгм Биофармасьютикалс, Инк. Связывающие белки и способы их применения
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
US10456449B2 (en) 2014-06-16 2019-10-29 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
BR112016030947A2 (pt) 2014-07-17 2017-10-24 Novo Nordisk As mutagênese dirigida ao local de anticorpos trem-1 para diminuição de viscosidade
IL251834B2 (en) 2014-10-23 2023-09-01 Ngm Biopharmaceuticals Inc Pharmaceutical compositions containing peptide variants and methods of using them
SI3412302T1 (sl) 2014-10-24 2021-09-30 Bristol-Myers Squibb Company Modificirani FGF-21 polipeptidi in njihova uporaba
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
RU2729011C2 (ru) 2014-12-23 2020-08-03 Ново Нордиск А/С Производные fgf21 и их применения
US11638745B2 (en) 2015-05-20 2023-05-02 University of Pittsburgh—Of the Commonwealth Cvctom of Hierher Education Method to improve neurologic outcomes in temperature managed patients
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
EP3368059A4 (de) 2015-10-30 2019-03-27 Salk Institute for Biological Studies Behandlung von steroid-induzierter hyperglykämie mit fibroblastenwachstumsfaktor (fgf)-1-analoga
EP3377090B1 (de) 2015-11-09 2021-04-07 NGM Biopharmaceuticals, Inc. Verfahren zur behandlung von gallensäurebedingten erkrankungen
TW201731867A (zh) 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
CN106317226B (zh) * 2016-08-19 2017-09-05 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
WO2018032638A1 (zh) 2016-08-19 2018-02-22 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CA3034399A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
EP3678686A1 (de) 2017-09-08 2020-07-15 Bristol-Myers Squibb Company Modifizierter fibroblasten-wachstumsfaktor 21 (fgf-21) für die verwendung in verfahren zur behandlung von nichtalkoholischer steatohepatitis (nash)
CN111518770B (zh) 2017-12-19 2023-01-06 北京吉源生物科技有限公司 一种表达glp1和fgf21的干细胞及其用途
US11679143B2 (en) 2018-02-08 2023-06-20 Sunshine Lake Pharma Co., Ltd. FGF21 variant, fusion protein and application thereof
JP2021519594A (ja) 2018-04-02 2021-08-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｔｒｅｍ−１抗体およびその使用
PE20210632A1 (es) 2018-07-03 2021-03-23 Bristol Myers Squibb Co Formulaciones de fgf-21
US11542309B2 (en) 2019-07-31 2023-01-03 Salk Institute For Biological Studies Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose
JP2023501515A (ja) * 2019-11-12 2023-01-18 テクニッシェ ウニヴェルズィテート ミュンヘン ヒトＩＬ－２７αサブユニットの均質ムテイン
EP4087612A1 (de) 2020-01-08 2022-11-16 Bristol-Myers Squibb Company Fgf-21-konjugatformulierungen
WO2021139744A1 (en) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugates of fusion proteins of glp-1 and fgf21
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
JP2023538533A (ja) 2020-08-07 2023-09-08 ブリストル－マイヤーズ スクイブ カンパニー 線維症の処置のための、ｃｃｒ２／５拮抗剤と組み合わせたｆｇｆ２１
WO2022115597A1 (en) 2020-11-25 2022-06-02 Bristol-Myers Squibb Company Methods of treating liver diseases
CN113633756A (zh) * 2021-06-17 2021-11-12 温州医科大学 Fgf21温敏缓释载体和基因修饰方法以及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301583D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Yeast strain and methods for expressing heterologous proteins in yeast
KR960704932A (ko) * 1994-08-12 1996-10-09 에이치. 에스. 리헤이 당단백질 호르몬 4개조의 단일-사슬 형태(single-chain forms of the glycoprotein hormone quartet)
JP4334615B2 (ja) * 1994-08-12 2009-09-30 ワシントン・ユニバーシティ 糖タンパク質ホルモンカルテットの一本鎖形態
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
WO2001018209A1 (en) 1999-09-10 2001-03-15 Curagen Corporation Fibroblast growth factor polypeptide and nucleic acids encoding same
ES2335386T3 (es) * 1999-11-18 2010-03-26 Novartis Vaccines And Diagnostics, Inc. Gen fgf-21 humano y productos de expresion genica.
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
AU1628101A (en) 1999-11-22 2001-06-04 Millennium Pharmaceuticals, Inc. Jaffa, a novel fibroblast growth factor family member and uses therefor
AU2002322394A1 (en) * 2001-07-30 2003-02-17 Eli Lilly And Company Method for treating diabetes and obesity
CA2468610A1 (en) 2002-01-15 2003-07-24 Eli Lilly And Company Method for reducing morbidity and mortality in critically ill patients
KR20060135648A (ko) * 2003-12-10 2006-12-29 일라이 릴리 앤드 캄파니 섬유모세포 성장인자 21의 뮤테인
US7576190B2 (en) * 2004-05-13 2009-08-18 Eli Lilly And Company FGF-21 fusion proteins

Also Published As

Publication number Publication date
EA200700533A1 (ru) 2007-08-31
JP2008511323A (ja) 2008-04-17
ATE444307T1 (de) 2009-10-15
EP1789442A2 (de) 2007-05-30
WO2006028595A3 (en) 2007-01-18
PT1789442E (pt) 2009-11-11
EP1789442B1 (de) 2009-09-30
NO20071327L (no) 2007-05-29
CN101010338B (zh) 2011-06-15
CA2575753A1 (en) 2006-03-16
HRP20090597T1 (hr) 2009-12-31
ES2332057T3 (es) 2010-01-25
CN101010338A (zh) 2007-08-01
EP2161281A1 (de) 2010-03-10
AU2005283025A1 (en) 2006-03-16
BRPI0514790A (pt) 2008-06-24
IL181573A0 (en) 2007-07-04
WO2006028595A2 (en) 2006-03-16
KR20070050454A (ko) 2007-05-15
MX2007002616A (es) 2007-05-16
US7582607B2 (en) 2009-09-01
SI1789442T1 (sl) 2010-01-29
US20080103096A1 (en) 2008-05-01
KR100854198B1 (ko) 2008-08-26
DK1789442T3 (da) 2009-11-16
JP4809352B2 (ja) 2011-11-09
EA011390B1 (ru) 2009-02-27
AU2005283025B2 (en) 2011-06-30
PL1789442T3 (pl) 2010-02-26

Similar Documents

Publication Publication Date Title
ATE444307T1 (de) Muteine des fibroblasten-wachstumsfaktors 21
WO2006065582A3 (en) Muteins of fibroblast growth factor 21
ATE430197T1 (de) Fibroblasten wachstumsfaktor-ähnliche polypeptide
DK1317537T3 (da) Sammensætninger og fremgangsmåder med G-CSF analoger
EA200800368A1 (ru) Гликозилированный il-7, получение и применение
DK1781782T3 (da) Modificerede vitamin K-afhængige polypeptider
EP2851422A3 (de) CD34neg Stammzellen zur Behandlung von gastrointestinalen Erkrankungen
ATE454403T1 (de) Menschliche koagulationsfaktor vii polypeptide
HK1129128A1 (en) Recombinant human interferon-like proteins
WO2003008449A8 (en) Ntb-a, a surface molecule involved in natural killer cells activity
WO2006046073A3 (en) C1q related protein
WO2006083516A3 (en) Modified cyanovirin-n polypeptide
WO2006053134A3 (en) Deamidated interferon-beta
JP2004537284A5 (de)
WO2006025995A3 (en) Compositions and methods using md-2 mutants and chimeric proteins
EA200700425A1 (ru) Гликопротеин клеточной поверхности
WO2003033723A3 (en) Vectors for expressing multiple transgenes
DE60139113D1 (de) 18477, eine menschliche proteinkinase und deren verwendung
WO2008020968A3 (en) Recombinant interferon-beta with enhanced biological activity
ATE444362T1 (de) Onkogen, davon abgeleitetes rekombinantes protein und dessen verwendung
EA200600956A1 (ru) Молекулы-антагонисты цитокинов
WO2002058716A3 (en) Treatment of inflammatory bowel disease using growth factors
EP1679372A4 (de) Neues plexin-polypeptid, dieses codierende dna und verwendung davon
RU2008130819A (ru) Способ продукции рекомбинантной стафилокиназы при регулировании уровня кислорода

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN